Fleming Harold Edward 4

What Happened
Harold Edward Fleming, a director of CRISPR Therapeutics AG (CRSP), was granted a derivative award on 2026-06-05 covering 13,000 shares. The Form 4 reports the acquisition amount as $0.00 (non‑cash award). This was an award/grant (transaction code A), not an open‑market purchase or sale; total cash value or exercise price is not provided in the excerpt.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (filed within the standard 2 business‑day window).
• Reported acquisition: 13,000 derivative securities (grant) at $0.00.
• Shares owned after the transaction: Not specified in the provided excerpt — see the full Form 4 for post‑transaction holdings.
• Footnote: The award are options that vest and become exercisable in 12 equal monthly installments (first vesting on June 30, 2026); final vesting occurs on the earlier of the one‑year anniversary of the grant or the 2027 Annual Meeting, contingent on continued service.
• Transaction code: A = Award/Grant (derivative securities).

Context
This was a compensation-related option grant to a director that vests monthly over up to one year. Such grants are commonly part of director compensation and are not the same as an outright purchase or sale; they do not, by themselves, indicate an immediate market bet. For full details (exercise price, total potential value, and exact post‑grant holdings), review the complete Form 4 filing (Accession: 0001193125-26-264289).